 WATERTOWN, Mass., Jan. 03, 2021 GLOBE NEWSWIRE -- EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT, a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong 1477.HK, has made a 15.7 million equity investment in EyePoint. Under the terms of the agreement, Ocumension has purchased approximately 3.01 million shares of EyePoints common stock at a five-day trailing volume weighted average price as of the close of trading on December 29, 2020 of approximately 5.22 per share. 